Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Shares Outstanding (Diluted Average) (2018 - 2025)

Historic Shares Outstanding (Diluted Average) for United Therapeutics (UTHR) over the last 11 years, with Q3 2025 value amounting to $48.1 million.

  • United Therapeutics' Shares Outstanding (Diluted Average) fell 82.47% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year decrease of 82.47%. This contributed to the annual value of $48.5 million for FY2024, which is 241.45% down from last year.
  • Latest data reveals that United Therapeutics reported Shares Outstanding (Diluted Average) of $48.1 million as of Q3 2025, which was down 82.47% from $48.5 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $49.7 million in Q3 2023 and a low of $46.4 million during Q1 2021
  • For the 5-year period, United Therapeutics' Shares Outstanding (Diluted Average) averaged around $48.5 million, with its median value being $48.5 million (2022).
  • Per our database at Business Quant, United Therapeutics' Shares Outstanding (Diluted Average) surged by 672.65% in 2021 and then plummeted by 241.45% in 2024.
  • Quarter analysis of 5 years shows United Therapeutics' Shares Outstanding (Diluted Average) stood at $47.3 million in 2021, then increased by 2.54% to $48.5 million in 2022, then grew by 2.47% to $49.7 million in 2023, then fell by 2.41% to $48.5 million in 2024, then fell by 0.82% to $48.1 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $48.1 million for Q3 2025, versus $48.5 million for Q2 2025 and $48.6 million for Q1 2025.